Hypophosphatemia caused by increased fibroblast growth factor 23 (FGF23) is a significant AE following FCM administration, but FDI does not affect FGF23 levels, and is not associated with significant hypophosphatemia [22]. Here, FGF23 is linked to hypophosphatemia.